TABLE 4.
Comparison of carbapenemase production and molecular testing results for carbapenem-resistant Enterobacterales and carbapenem-resistant Pseudomonas aeruginosa isolates according to the Antibiotic Resistance Laboratory Network, 2017 to 2019
| Isolate characteristic(s) | No. (%) of carbapenem-resistant isolates |
|
|---|---|---|
| Enterobacterales a | P. aeruginosa | |
| Totala | 16,980 | 4,759 |
| Carbapenemase production+, PCR+ | 9,638 (57) | 468 (10) |
| Carbapenemase production−, PCR− | 6,841 (40) | 4,156 (87) |
| Carbapenemase production+, PCR− | 443 (3) | 117 (2) |
| Carbapenemase production−, PCR+ | 58 (<1) | 18 (<1) |
a
Excludes Serratia isolates with AST phenotypes consistent with the presence of blaSME (Serratia marcescens enzyme) (defined as resistant to carbapenems and susceptible to third-generation cephalosporins), Enterobacter species isolates with AST phenotypes suggestive of hyperproduction of AmpC (defined as resistant to cefotaxime, ceftriaxone, and ceftazidime and susceptible to cefepime), and isolates with missing modified carbapenem inactivation method (mCIM) or PCR testing results.